By mimicking the way viruses bind to host cells, NanoViricides is developing unique
nanomedicines that are able to trick, trap and destroy these pathogens. To download the full article, please sign in.
NanoViricides, Inc. is a development stage company with a unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines, that we call "nanoviricides®". Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. seasonal and potentially-epidemic influenzas and bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.